U.S. Stock News

Soft earnings didn't appear to concern Jabil Inc.'s ( NYSE:JBL ) shareholders over the last week. We think that the...

As U.S. markets experience slight declines amid rising Treasury yields and uncertainty surrounding Federal Reserve policies, investors are increasingly on the lookout for stocks that may be undervalued relative to their intrinsic worth. In this environment, identifying stocks like CVB Financial that could potentially offer value involves assessing factors such as financial health, market position, and growth potential in relation to current economic conditions.

As the U.S. stock market grapples with rising Treasury yields and a cautious Federal Reserve outlook, investors are keenly observing growth companies where insiders have significant ownership stakes. In such uncertain times, stocks with high insider ownership can signal confidence in the company's long-term prospects, making them an intriguing consideration for those navigating today's complex market landscape.

As of January 2026, the U.S. stock market is experiencing some turbulence, with major indexes posting weekly losses amid rising Treasury yields and uncertainty surrounding Federal Reserve policies. In this context, penny stocks—though often considered a niche investment area—can still present intriguing opportunities for growth, particularly in smaller or newer companies with strong financial foundations. This article will explore three penny stocks that stand out for their balance sheet...

DT Midstream, Inc.'s ( NYSE:DTM ) price-to-earnings (or "P/E") ratio of 30.4x might make it look like a strong sell...

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders have had their patience rewarded with a 53% share price jump in...

Some Applied Digital Corporation ( NASDAQ:APLD ) shareholders may be a little concerned to see that the Chairman...

Despite an already strong run, MACOM Technology Solutions Holdings, Inc. ( NASDAQ:MTSI ) shares have been powering on...

With no single headline event driving attention today, investors are watching WaterBridge Infrastructure (WBI) following recent price swings and mixed return patterns over the past week, month, and past three months. See our latest analysis for WaterBridge Infrastructure. Over the year to date, WaterBridge Infrastructure’s share price has moved to $21.55, with a 7 day share price return of 6.89% and a 90 day share price return of an 11.75% decline, which suggests recent momentum has cooled...

Event context and recent share performance Collegium Pharmaceutical (COLL) has drawn attention after recent trading, with the share price at US$45.60 and returns showing a 2.8% decline over the past day and 5.3% decline over the past week. See our latest analysis for Collegium Pharmaceutical. While the recent 1 day and 7 day share price returns are negative, the 90 day share price return of 28.96% and 1 year total shareholder return of 36.73% suggest momentum has been building over a longer...

In early January 2026, Zymeworks reported positive Phase 3 HERIZON-GEA-01 results for its HER2-targeted therapy Ziihera in advanced gastroesophageal adenocarcinoma, alongside a series of leadership changes including new board and executive appointments and key retirements. A distinctive angle in this news is that the HERIZON-GEA-01 data could unlock up to US$440.0 million in potential approval-related milestones for Ziihera across the US, Europe, Japan, and China, adding financial...

As the U.S. market grapples with rising Treasury yields and uncertainty surrounding Federal Reserve decisions, investors are keenly observing potential opportunities amid recent index declines. In this environment, identifying undervalued stocks can be crucial for those looking to capitalize on discrepancies between market price and estimated value, as these stocks might offer growth potential despite broader economic challenges.

As U.S. markets face weekly losses amid climbing Treasury yields, investors are increasingly focused on companies with strong fundamentals and insider confidence to navigate these uncertain times. In this landscape, growth companies with high insider ownership stand out, as they often signal management's belief in the firm's potential and align interests between executives and shareholders.

As the U.S. markets grapple with recent declines and rising Treasury yields, investors are keenly observing potential opportunities in various sectors. Penny stocks, while often seen as relics of past market trends, continue to offer intriguing possibilities for those willing to explore smaller or newer companies at accessible price points. By focusing on solid financials and growth potential, these stocks can present unique opportunities for investors looking to tap into under-the-radar...

As the U.S. market grapples with rising Treasury yields and a cautious Federal Reserve outlook, small-cap stocks are navigating a landscape marked by both challenges and opportunities. In this environment, identifying promising small caps requires a keen eye for companies with robust fundamentals that can weather economic fluctuations and capitalize on niche market demands.

The recent 11% drop in AIFU Inc.'s ( NASDAQ:AIFU ) stock could come as a blow to insiders who purchased CN¥12.3m worth...

We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits...

In recent days, Scotiabank and several other research firms shifted their views on American Homes 4 Rent, updating ratings and reassessing their outlook on the single‑family rental REIT. This cluster of analyst actions offers fresh information on how the market is reassessing American Homes 4 Rent’s risk‑reward profile and business outlook. Next, we’ll examine how this wave of analyst rating changes could influence American Homes 4 Rent’s investment narrative and future expectations. Rare...

Oruka Therapeutics (ORKA) drew fresh investor attention after reporting encouraging interim Phase 1 data for ORKA-002, highlighting a long half-life and sustained IL-17 inhibition that could support less frequent dosing in psoriasis and hidradenitis suppurativa. See our latest analysis for Oruka Therapeutics. The positive ORKA-002 readout and recent conference presence appear to have kept interest high, with a 1-day share price return of 2.77% and year to date share price return of 18.15%...

Key Insights Given the large stake in the stock by institutions, Zhihu's stock price might be vulnerable to their...

Key Insights Aptera Motors' significant insider ownership suggests inherent interests in company's expansion A total of...

GoodRx Holdings (NASDAQ:GDRX) has had a rough three months with its share price down 31%. However, the company's...

The board of Carriage Services, Inc. ( NYSE:CSV ) has announced that it will pay a dividend on the 2nd of March, with...

Key Insights Significantly high institutional ownership implies Cytek Biosciences' stock price is sensitive to their...